The Drug Development Letter

Home
Archive
About
Debate over pembrolizumab dosing gives rise to a national guidance on de-escalation strategies and off-label use
"You may wonder why most dose optimisation and de-escalation studies come from the Netherlands"
 • 
Sahar van Waalwijk
1
Challenges with Reproducibility
My thoughts after a reproducibility paper was retracted.
 • 
Vinay Prasad
2
Lu-PSMA and the need to 'educate' medical professionals about its use.
A dive into the VISION trial, PSMAfore trial, and the questionable practices of the sponsor.
 • 
John-John Schnog
, 
Michael Samson
, and 
Ashley Duits
6
Most Popular
View all
The scattergun approach in research - a deep dive into CDK4/6 inhibitors tested in the neoadjuvant setting.
 • Sahar van Waalwijk
How to read and interpret a cancer clinical trial
 • Vinay Prasad
6
Eli Lilly's Court Victory: Dutch Agency Must Reevaluate Abemaciclib Amid Controversy
 • Sahar van Waalwijk
20
Relapsed cancer patients die so asymptomatic pre-cancer patients can go on trial
 • Vinay Prasad
1
How to read and interpret Kaplan Meier Curves
 • Vinay Prasad
Giving adjuvant Xeloda to Biliary cancer was and is crazy
 • Vinay Prasad
Immune Checkpoint Inhibitors: 10-Year Results in Melanoma Are Now Out – Let's Reflect on These Impressive Advances.
Remarkable advances and remaining questions.
 • 
Timothée Olivier
5
The scattergun approach in research - a deep dive into CDK4/6 inhibitors tested in the neoadjuvant setting.
About forty trials enrolling thousands of patients have been launched since 2010.
 • 
Sahar van Waalwijk
Should US Taxpayers Have Payed For The AMBASSADOR Trial? A poll.
The AMBASSADOR trial has been published in the New England Journal of Medicine, and presented at ESMO 2024.
 • 
Vinay Prasad
5
An Educational Opportunity... ESMO2024 and the LEAP-012 trial!
How a colleague's well-intended comments prompted me to explain several common misunderstandings that should be better taught during oncology training.
 • 
Vinay Prasad
2
Special ESMO 2024 edition !
Timothee Olivier and I discuss the top ESMO 2024 abstracts!
 • 
Vinay Prasad
 and 
Timothée Olivier
36:02
What is a "Seeding Trial"? Tivozanib and the TiNivo-2 trial in renal cancer #ESMO 2024
A thread!
 • 
Vinay Prasad
Driver mutation lung cancer
What is going on?
 • 
Vinay Prasad
1
37:22
The Drug Development Letter
The Drug Development Letter
We cover all aspects of pharmaceutical drug development; early, late phase and FDA pivotal trials; Focus on oncology, but also cover important cardiology, neurology and drugs for rare diseases

The Drug Development Letter

AboutArchiveSitemap
© 2024 Vinay Prasad
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great culture